The symptoms of overdose include irritability, nervousness, tremor, palpitations, convulsions, urinary retention and hypertension, restlessness, dry mouth, anxiety, insomnia, nausea, vomiting, tachycardia, cardiac arrhythmias and possible tolerance to pseudoephedrine.
Overdose should be treated by general supportive measures. Respiratory and circulatory function should be maintained by supportive measures. Catheterisation of the bladder may be required.
The benefit of gastric decontamination is uncertain. Consider activated charcoal (charcoal dose: 50 g for adults; 1g/kg for children). Optimal effects are within 1 hour of ingestion of more than a toxic dose. Volunteer studies suggest that there is reduced absorption within 2 hours and efficacy declines thereafter. Alternatively consider gastric lavage in adults within 1 hour of a potentially life-threatening overdose. Monitor pulse, blood pressure and cardiac rhythm. Treat any hypertension or convulsions as necessary.
Asymptomatic patients should be observed for 4 hours or 8 hours if a slow release product has been taken.
24 months.
Galpseud Linctus should not be used in patients hypersensitive to pseudoephedrine, or any of the other ingredients.
Patients receiving monoamine oxidase inhibitors or who have received these agents in the last two weeks. Patients using other sympathomimetic decongestants or beta-blockers..
Patients with cardiovascular disease including ischaemic heart disease, occlusive vascular disease and hypertension.
Children under 6 years of age.
Patients with:
- Severe renal impairment
- Phaeochromocytoma
- Diabetes
- Hyperthyroidism
- Closed angle glaucoma.
None stated.
Citric acid monohydrate
Sodium hydroxybenzoates (E215, E217 & E219)
Alcohol 96%
Amaranth (E123)
Sunset yellow FCF (E110)
Carmellose sodium
Saccharin sodium
Menthol
Condensed milk flavour (F12516)
Orange flavour (17.40.7040)
Glycerol
Purified water
Oral liquid.
A deep orange coloured liquid.
The following side effects may be associated with the use of pseudoephedrine:
(frequencies not known: cannot be estimated from the available data).
Immune system disorders:
Hypersensitivity reactions - cross-sensitivity may occur with other sympathomimetics.
Psychiatric disorders:
Hallucinations (particularly in children), insomnia, sleep disturbances, anxiety, restlessness, irritability, excitability, psychotic disorder has occurred rarely following misuse of pseudoephedrine.
Nervous system disorders:
Headache, tremor, dry mouth.
Eye disorders:
Angle-closure glaucoma.
Cardiac disorders:
Tachycardia, palpitations, arrhythmia.
Vascular disorders:
Hypertension, impaired circulation to the extremities.
Gastrointestinal disorders:
Nausea, vomiting.
Skin and subcutaneous tissue disorders:
Fixed drug eruption in the form of erythematous nodular patches, rash.
Renal and urinary disorders:
Urinary retention.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
There are no pre-clinical data of relevance to the prescriber, which are additional to those already included in other sections of the SmPC.
Indicated for the relief of nasal, sinus and upper respiratory congestion.
Pharmacotherapeutic Group: Nasal Decongestants for Systemic Use, Sympathomimetics. ATC code : R01B A02
Pseudoephedrine has direct and indirect sympathomimetic activity and is an orally effective upper respiratory tract decongestant.
Pseudoephedrine is substantially less potent than ephedrine in producing both tachycardia and elevation in systolic blood pressure and considerably less potent in causing stimulation of the central nervous system.
Pseudoephedrine hydrochloride is readily and completely absorbed from the gasto-intestinal tract. It is resistant to metabolism by monoamine oxidase and is largely excreted unchanged in the urine.
18/02/2015
Galpseud Linctus
Thornton & Ross Ltd
Linthwaite
Huddersfield
HD7 5QH
United Kingdom
Store below 25°C. Protect from light.
Amber HDPE 2 litre Winchester with a polypropylene cap.
PL 00240/0350
There are limited data from the use of pseudoephedrine in pregnant women. It is advised that pseudoephedrine should be avoided during pregnancy, particularly during the first trimester, as defective closure of the abdominal wall (gastroschisis) has been reported very rarely in new-borns after first trimester exposure.
Pseudoephedrine has been detected in human milk with a small percentage of the total maternal dose potentially administered to the suckling infant. The use of pseudoephedrine should be avoided during breast feeding as lactation may be suppressed, and irritability and disturbed sleep have been reported in breast fed infants.
Caution should be used in prescribing Galpseud Linctus for patients with prostatic enlargement or bladder dysfunction.
Also use with caution in patients with severe hepatic impairment, or with mild to moderate renal impairment.
If any of the following occur, Galpseud Linctus should be stopped
- Hallucinations
- Restlessness
- Sleep disturbances.
Amaranth (E123) and Sunset Yellow (E110) may cause allergic reactions.
Sodium hydroxybenzoates (E215, E217 & E219) may cause allergic reactions (possibly delayed).
Galpseud Linctus contains 1.9 vol% ethanol (alcohol), ie. up to 154 mg per dose (10 ml), equivalent to 4 ml of beer or 2 ml of wine. Harmful for those suffering from alcoholism. To be taken into account in pregnant or breast feeding women, children and high risk groups such as patients with liver disease, or epilepsy.
Do not exceed the stated dose.
Keep out of the sight and reach of children.
None stated.
For oral administration.
Adults and children over 12 years:
Two 5ml spoonfuls three times daily.
Children:
6-12 years: 5ml three or four times daily.
Elderly:
Adult dose is appropriate.
None stated.
23/07/2008
Caution should be exercised with patients receiving other sympathomimetic agents (e.g. avoid use with apraclonidine), appetite suppressants or amphetamine-like psychostimulants, as there is a risk of hypertension.
Pseudoephedrine may antagonise the pressor effects of antihypertensive agents, such as adrenergic neurone blockers, and severe hypertension may occur in patients receiving beta-blockers. Hypertensive crisis may occur if pseudoephedrine is co-administered with MAOIs. Concomitant use of pseudoephedrine should be avoided with MAOIs including rasagiline and selegiline, or RIMAs such as moclobemide.
There may be an increased risk of arrhythmias if pseudoephedrine is given to patients receiving cardiac glycosides, quinidine, volatile anaesthetics such as cyclopropane, or halothane, or anticholinergic drugs such as tricyclic antidepressants. Pseudoephedrine also increases the risk of ergotism if used with ergot alkaloids, ergotamine and methysergide.
The effects of pseudoephedrine may be antagonised by antipsychotics and its absorption rate may be reduced by kaolin.
The effects of pseudoephedrine may be increased by doxapram and oxytocin (as there is a risk of hypertension) and its absorption may be increased by aluminium hydroxide.
The antibacterial agent furazolidone is known to cause progressive inhibition of monoamine oxidase (a metabolite of furazolidone is a MAOI). Although there have been no reports of hypertensive crisis, it may not be administered concurrently with Galpseud Linctus.
